Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
about
Current Research Therapeutic Strategies for Alzheimer's Disease TreatmentEffects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell functionSerotonin, neural markers, and memoryTherapeutic Targeting of AutophagyAVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.The Serotonin Receptor 6 Antagonist Idalopirdine and Acetylcholinesterase Inhibitor Donepezil Have Synergistic Effects on Brain Activity-A Functional MRI Study in the Awake RatIdalopirdine as a treatment for Alzheimer's disease.5-HT6 receptor agonism facilitates emotional learning.Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity.Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.Peripheral serotonin-mediated system suppresses bone development and regeneration via serotonin 6 G-protein-coupled receptorInvestigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.Potential serotonergic agents for the treatment of schizophrenia.Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia.AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation.5-HT6 receptor blockade regulates primary cilia morphology in striatal neurons.Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue.Emerging amyloid and tau targeting treatments for Alzheimer's disease.Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer's disease by regulating cilia function.5-HT6 Receptor Agonist and Antagonist Against β-Amyloid-Peptide-Induced Neurotoxicity in PC-12 Cells.Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating.Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.Autophagic compound database: A resource connecting autophagy-modulating compounds, their potential targets and relevant diseases.Reducing falls in Parkinson's disease: interactions between donepezil and the 5-HT6 receptor antagonist idalopirdine on falls in a rat model of impaired cognitive control of complex movements.Dysregulation of 5-hydroxytryptamine 6 receptor accelerates maturation of bone-resorbing osteoclasts and induces bone loss.Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease.A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.Alzheimer's disease drug development pipeline: 2018.A Computational Systems Pharmacology Approach to Investigate Molecular Mechanisms of Herbal Formula Tian-Ma-Gou-Teng-Yin for Treatment of Alzheimer’s Disease.Cognitive composite score association with Alzheimer's disease plaque and tangle pathology
P2860
Q26765530-8FB3947C-DF18-4228-8A49-DB0337E3E965Q26783101-A659B069-F7AD-424F-987A-746B040D1B75Q26800204-3B9F0D9C-7D56-4BD6-B15B-85F835CACE86Q28078117-A7FCFA1B-30FF-47B8-BAD1-3D3B8E9456C8Q30377178-A4322D4F-2BDD-4EFA-B24D-7FCCF8E4E2CBQ33785842-DE6D13FB-98F8-44FA-A8F5-AAEAC81559D6Q35645744-BC1B967B-F172-4B28-A733-8D3ECD3DF671Q36097366-E5934D1E-FDDE-4381-9B11-100E424C182BQ36273778-1223C319-4C59-4CD7-ABE1-93C0CBA225D1Q36588166-BBDFC5B6-0583-4772-A015-E9EC81D37EE3Q37223396-6B3FCFC7-674D-4C50-A2C4-320D3951A1DEQ38627971-EB7EB696-933A-49A1-BBC2-456CFB5B4674Q38635792-7C539A89-D4C6-4979-A74B-E8C775330007Q38737187-FDFD4855-6659-46B0-BE09-8418EA604C44Q38760655-A69DBE0A-2177-4954-90F2-742CD904AF88Q39021418-78FEEBA5-E3E0-4825-B06C-1F9109A4F71DQ39022532-5B3AC6A7-18B1-46EA-BF8A-C4668803C8E3Q39027024-56D7929F-5DD3-4F21-8E10-748739DC7B06Q39296311-730F1A23-61F4-44D4-99E1-52FFB64EBA5DQ39296351-D336A4F4-D03D-4704-99FF-CD2AAACCB1B1Q41695275-0422A15E-F30F-401A-A36E-22E771C99F6CQ46407556-FF5F0EEA-4F55-4D39-A265-5BBC5A0F568AQ47172455-BBA5D459-511F-4CDE-B4CB-82995FF6CA42Q47557467-BD7E363A-7C58-4EC3-A713-B648B4D2DA27Q47864357-25C97695-A378-4DBB-A760-E830923529D0Q50633165-9E4D7AC4-036F-487E-8D79-7FD898F3B238Q55158837-913141B7-7B1A-405A-8552-99A3EB6A2753Q55297754-7993B6DF-3C75-4952-9157-F3F480A276A6Q55304897-EAF568D6-9918-43E9-B0F5-D8EECECF8733Q55357444-16C89733-B575-4683-B682-AF0E95B0C194Q55530937-3D732F40-3706-47AF-945C-442B11C23775Q58751300-5FAF7643-7C6E-4775-8A24-EC75A2F27B03
P2860
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@ast
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@en
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@nl
type
label
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@ast
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@en
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@nl
prefLabel
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@ast
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@en
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@nl
P2093
P921
P1433
P1476
Safety and efficacy of idalopi ...... cebo-controlled phase 2 trial.
@en
P2093
David Wilkinson
Eskild Colding-Jørgensen
Kristian Windfeld
P304
P356
10.1016/S1474-4422(14)70198-X
P577
2014-10-05T00:00:00Z